An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics

J Neural Transm Gen Sect. 1991;84(3):233-6. doi: 10.1007/BF01244973.

Abstract

Eleven schizophrenics (7 females) displaying an acute psychotic episode received the partial dopamine agonist terguride in doses up to 2 mg per day. Improvement in terms of positive symptoms reduction was observed in two cases only. In contrast, in a previous clinical trial targeted at negative schizophrenic symptoms, the majority of the patients appeared to have benefited from terguride application.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Antipsychotic Agents / pharmacology
  • Antipsychotic Agents / therapeutic use*
  • Drug Evaluation
  • Female
  • Humans
  • Lisuride / analogs & derivatives*
  • Lisuride / pharmacology
  • Lisuride / therapeutic use
  • Psychological Tests
  • Receptors, Dopamine / drug effects
  • Receptors, Dopamine / physiology
  • Schizophrenia / drug therapy*
  • Schizophrenia / physiopathology
  • Schizophrenia, Paranoid / drug therapy
  • Schizophrenia, Paranoid / physiopathology

Substances

  • Antipsychotic Agents
  • Receptors, Dopamine
  • dironyl
  • Lisuride